A Forged Prescription Pad, a Six-Year Ban: Ruti Aga's Case Is About Medical Governance, Not Steroids

The Athletics Integrity Unit (AIU) statement released on Thursday breaks in three places, one after another. First: the clinic named on the prescription does not exist. Second: the person who wrote it was not a doctor, but a family member of the athlete, with no medical registration. Third: the family member explained the document by saying he had used "an old prescription pad from a former workplace" — and that clinic publicly disowned the pad.

Three verifications, three failures. Behind all three sits a fourth thing mentioned in a single line of the statement: a knee injury. Ruti Aga of Ethiopia, 32, has been banned for six years. Two years for the presence violation — a prohibited substance in her system; four years for tampering. The addition is straightforward, and it is the real arithmetic of this story.

Aga's in-competition sample was collected after she won a half marathon in China in March. It contained methylprednisolone. Several reports described it as a "prohibited steroid." That is technically wrong, and in this specific case the error is not a matter of vocabulary — it changes the direction of the entire defence. Methylprednisolone is not an anabolic steroid, the WADA Prohibited List S1 class; it is a glucocorticoid, class S9. And under the current List, S9 glucocorticoids are prohibited in-competition only — by injection, oral or rectal routes. Which means a therapeutic knee injection is entirely legal out of competition. It becomes a violation only if residues remain in the body during competition.

The first counter-intuitive point sits right there: Aga had a legitimate defence available — route and timing. When was the injection given, by which route, and how much time did the substance have to metabolise before the race? Real medical records could have answered all three. What was presented to the AIU was not a record but a fabricated document. And when you substitute a fake document for a real one, you prove you did not have the real one.

This is where the case stops being an individual lapse and becomes evidence of a system. In the spring of 2026, when I began that six-episode audio series on the empty track from Chicago, my first question to every athlete was the same — "who do you lean on?" Eighteen athletes, and not one said the federation. They named a coach, a parent, or a physio with no formal standing. Aga's case is the dark version of that same answer. A 32-year-old elite marathoner did not have a team physician. She had a relative with an old prescription pad, documenting a knee treatment that never existed.

The sequence of responses here is the story itself: the March result, then the sample, then the provisional suspension dated 10 September, then Thursday's statement, then a silence still being counted. Three separate checks were run on one document — the writer's registration, the clinic's existence, the pad's origin. That is the one kind of verification communiqués cannot perform.

There is an economic layer that cannot be skipped. Aga's career divides in two: the 2026 Tokyo Marathon title and three runner-up finishes at World Marathon Majors — genuine elite level; and afterwards a model of selective racing between Majors and Asian label races, where appearance fees are the primary income. The Chinese label circuit is attractive to East African marathoners precisely because of that — large fees, few races, low visibility. And precisely for that reason it is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races, and the athlete stands between them.

One thing the statement does not address, and it lingers: what happened to the March result and its prize money? Standard AIU practice voids the result of the competition where the sample was collected, but the scope was not clarified. The 2026 Tokyo title is untouched, because the violation attaches to a later race. That distinction matters — an athlete's career record and an athlete's single day are different things, and collapsing them is the record-book inflation this beat should be auditing, not practising.

The sanction architecture is worth reading closely. Two years for presence is what you get when a substance is classified as specified and intent is not proven. Four years for tampering is the Code's standard. Note that the panel declined the no-significant-fault reduction, which would otherwise have cut the presence sanction. And backdating to 10 September is not a discount: provisional suspension time counts against the ban, so the athlete gains nothing in real terms.

Here is the part least written about. A six-year ban has been imposed for a substance with no proven endurance-performance benefit. That number will be cited from both directions — as evidence of AIU rigour, and as evidence of disproportionate enforcement against African road runners. What gets said less often is that the real offence was not the substance but the document. And the reason a document had to be forged sits not in the athlete's character but in a system that pushes injured runners toward hiding pain quietly, because skipping a race means surrendering a fee. Chronic knee pathology is the most common failure mode in high-mileage marathoners, and a steroid injection is the cheapest available fix.

It also needs recording that no statement came from the Ethiopian federation. Only the AIU spoke. When a 32-year-old's career ends, a national body's silence is itself a statement. Protect the athlete, prosecute the administration: the injury is hers, but not helping her find a credentialed treatment pathway is not.

What to watch. The appeal window at the Court of Arbitration for Sport typically runs about 21 days from the reasoned decision; a document-based finding is very hard to overturn, so the odds are low. More consequential is whether the agent or management is investigated — the statement names only the family member, and no athlete finds a prescription pad alone. And the largest question: inside the same training cluster, served by the same informal medical network, how many more prescriptions are sitting in a verification queue. A runner returning at 38 will not find room in Ethiopia's marathon depth — but that depth did not protect her either. What the empty track keeps saying after everyone leaves is usually not a verdict. It is a question: the next time a knee needs an injection, who writes the paper?